Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.46 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 4/20 | 0.44 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.43 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30683245 | 0.82 | BACE1 (0.45) | CALCRF2 | |
| SCHEMBL30504295 | 0.81 | CALCR (0.52) | CALCRKISS1RF2PTH1RCRHR1 | |
| SCHEMBL30262235 | 0.81 | CALCR (0.57) | CALCRF2CRHR1CRHR2 | |
| SCHEMBL30271074 | 0.80 | F2 (0.43) | CALCRF2 | |
| SCHEMBL30271070 | 0.80 | F2 (0.43) | CALCRF2 | |
| SCHEMBL29599778 | 0.79 | CALCR (0.43) | CALCRF2 | |
| SCHEMBL30136928 | 0.79 | GLP1R (0.47) | CALCRF2 | |
| SCHEMBL31721844 | 0.79 | OPRM1 (0.53) | F2 | |
| SCHEMBL9713882 | 0.78 | OPRD1 (0.46) | F2 | |
| SCHEMBL9713899 | 0.78 | OPRD1 (0.46) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | CALCR 2817/4885KISS1R 1078/4885F2 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.